Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
62,705.03 +3,143.56 (+5.28%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Trevi Therapeutics, Inc. (TRVI)
After hours:
| Previous close | 3.0100 |
| Open | 3.0200 |
| Bid | 3.0100 x 200 |
| Ask | 3.0400 x 200 |
| Day's range | 2.9800 - 3.1200 |
| 52-week range | 0.9700 - 4.0000 |
| Volume | |
| Avg. volume | 304,061 |
| Market cap | 212.714M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2900 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.33 |
PR NewswireTrevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 7, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31,
ZacksTrevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- PR Newswire
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.
